Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC3Y7O
|
|||
| Drug Name |
RG6296
|
|||
| Synonyms |
AFM-26
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 1 | [1] | |
| Company |
Affimed Therapeutics; Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | Inhibitor | [2] |
| Immunoglobulin gamma Fc receptor IIIA (FCGR3A) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04434469) A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genentech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.